A novel inhibitor of ARfl and ARv7 induces protein degradation to overcome enzalutamide resistance in advanced prostate cancer

• Main Authors: Yan Li (Author), Ya Chu (Author), Guangjiang Shi (Author), Xiaobin Wang (Author), Wanli Ye (Author), Chun Shan (Author), Dajia Wang (Author), Di Zhang (Author), Wei He (Author), Jingwei Jiang (Author), Shuqian Ma (Author), Yuhong Han (Author), Zhili Zhao (Author), Shijia Du (Author), Zhen Chen (Author), Zhiyu Li (Author), Yong Yang (Author), Chen Wang (Author), Xi Xu (Author), Hongxi Wu (Author)
• Format: Book
• Published: Elsevier, 2022-11-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Enzalutamide (ENZ) is a second-generation androgen receptor (AR) antagonist used for the treatment of castration-resistant prostate cancer (CRPC) and reportedly prolongs survival time within a year of starting therapy. However, CRPC patients can develop ENZ resistance (ENZR), mainly driven by abnorm...